|
Market Closed -
Hong Kong S.E.
11:08:05 05/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 0.5050 HKD | +3.06% |
|
+2.02% | +1.00% |
| 08-28 | Mabpharm Limited Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| 06-24 | Mabpharm Limited Receives Approval for New Drug Application of CMAB807X (Denosumab Injection) | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 258M | - | - | - | - | - |
| 74.16B | |||||
| 57.39B | |||||
| 47.64B | |||||
| 44.29B | - | - | - | - | - |
| 42.5B |
- Stock Market
- Stocks
- 2181 Stock
- Charts Mabpharm Limited
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
